Research programme: neurodegenerative disease therapeutics - Sanofi Genzyme/BBB Therapeutics

Drug Profile

Research programme: neurodegenerative disease therapeutics - Sanofi Genzyme/BBB Therapeutics

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Genzyme Corporation; to-BBB technologies
  • Developer BBB Therapeutics; Sanofi Genzyme
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurodegenerative disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in Netherlands (Liposomal)
  • 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics
  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top